company background image

High Fusion CNSX:FUZN Stock Report

Last Price


Market Cap







02 Oct, 2022


Company Financials
FUZN fundamental analysis
Snowflake Score
Future Growth0/6
Past Performance2/6
Financial Health1/6

FUZN Stock Overview

High Fusion Inc. focuses on developing and manufacturing branded products in the cannabis industry with a specific focus on flower, pro-rolls, vapes, edibles, and oil extracts for medical and adult recreational use in California, Colorado, and Oregon.

High Fusion Competitors

Price History & Performance

Summary of all time highs, changes and price drops for High Fusion
Historical stock prices
Current Share PriceCA$0.02
52 Week HighCA$0.18
52 Week LowCA$0.01
1 Month Change0%
3 Month Change0%
1 Year Change-80.95%
3 Year Change-99.17%
5 Year Change-99.26%
Change since IPO-98.46%

Recent News & Updates

Shareholder Returns

FUZNCA PharmaceuticalsCA Market

Return vs Industry: FUZN underperformed the Canadian Pharmaceuticals industry which returned -66.1% over the past year.

Return vs Market: FUZN underperformed the Canadian Market which returned -6.6% over the past year.

Price Volatility

Is FUZN's price volatile compared to industry and market?
FUZN volatility
FUZN Average Weekly Movement53.6%
Pharmaceuticals Industry Average Movement12.6%
Market Average Movement10.0%
10% most volatile stocks in CA Market18.0%
10% least volatile stocks in CA Market3.8%

Stable Share Price: FUZN is more volatile than 90% of Canadian stocks over the past 3 months, typically moving +/- 54% a week.

Volatility Over Time: FUZN's weekly volatility has increased from 32% to 54% over the past year.

About the Company

2004n/aJohn Durfy

High Fusion Inc. focuses on developing and manufacturing branded products in the cannabis industry with a specific focus on flower, pro-rolls, vapes, edibles, and oil extracts for medical and adult recreational use in California, Colorado, and Oregon. Its brand portfolio includes FLÏ edibles and vape product, Red Octopus and Dubbi Brothers, OutCo, and Thrive brands. The company also focuses on developing products and conducting research on the psychoactive cacti plants for use in modern medical and natural health product markets.

High Fusion Fundamentals Summary

How do High Fusion's earnings and revenue compare to its market cap?
FUZN fundamental statistics
Market CapCA$3.97m
Earnings (TTM)CA$766.07k
Revenue (TTM)CA$4.71m


P/E Ratio


P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
FUZN income statement (TTM)
Cost of RevenueCA$2.84m
Gross ProfitCA$1.88m
Other ExpensesCA$1.11m

Last Reported Earnings

Apr 30, 2022

Next Earnings Date


Earnings per share (EPS)0.0039
Gross Margin39.80%
Net Profit Margin16.25%
Debt/Equity Ratio308.0%

How did FUZN perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.


Is FUZN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score


Valuation Score 2/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for FUZN?

Other financial metrics that can be useful for relative valuation.

FUZN key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue3.2x
Enterprise Value/EBITDA-2.7x
PEG Ration/a

Price to Earnings Ratio vs Peers

How does FUZN's PE Ratio compare to its peers?

FUZN PE Ratio vs Peers
The above table shows the PE ratio for FUZN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average13.1x
EAST EastWest Bioscience
J Lotus Ventures
CLAS Claritas Pharmaceuticals
MDP Medexus Pharmaceuticals
FUZN High Fusion

Price-To-Earnings vs Peers: FUZN is good value based on its Price-To-Earnings Ratio (5.2x) compared to the peer average (13.1x).

Price to Earnings Ratio vs Industry

How does FUZN's PE Ratio compare vs other companies in the North American Pharmaceuticals Industry?

Price-To-Earnings vs Industry: FUZN is good value based on its Price-To-Earnings Ratio (5.2x) compared to the North American Pharmaceuticals industry average (12.2x)

Price to Earnings Ratio vs Fair Ratio

What is FUZN's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

FUZN PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio5.2x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate FUZN's Price-To-Earnings Fair Ratio for valuation analysis.

Share Price vs Fair Value

What is the Fair Price of FUZN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate FUZN's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate FUZN's fair value for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Future Growth

How is High Fusion forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score


Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as High Fusion has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Discover growth companies

  • Take a look at our analysis of FUZN’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • High Fusion competitive advantages and company strategy can generally be found in its financial reports archived here.

Past Performance

How has High Fusion performed over the past 5 years?

Past Performance Score


Past Performance Score 2/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: FUZN has a high level of non-cash earnings.

Growing Profit Margin: FUZN became profitable in the past.

Past Earnings Growth Analysis

Earnings Trend: FUZN has become profitable over the past 5 years, growing earnings by -4.8% per year.

Accelerating Growth: FUZN has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: FUZN has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (39.8%).

Return on Equity

High ROE: Whilst FUZN's Return on Equity (35.31%) is high, this metric is skewed due to their high level of debt.

Discover strong past performing companies

Financial Health

How is High Fusion's financial position?

Financial Health Score


Financial Health Score 1/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: FUZN's short term assets (CA$4.4M) do not cover its short term liabilities (CA$14.9M).

Long Term Liabilities: FUZN's short term assets (CA$4.4M) exceed its long term liabilities (CA$1.9M).

Debt to Equity History and Analysis

Debt Level: FUZN's net debt to equity ratio (290.2%) is considered high.

Reducing Debt: FUZN's debt to equity ratio has increased from 13% to 308% over the past 5 years.

Debt Coverage: FUZN's operating cash flow is negative, therefore debt is not well covered.

Interest Coverage: Insufficient data to determine if FUZN's interest payments on its debt are well covered by EBIT.

Balance Sheet

Discover healthy companies


What is High Fusion current dividend yield, its reliability and sustainability?

Dividend Score


Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

High Fusion Dividend Yield vs Market
How does High Fusion dividend yield compare to the market?
SegmentDividend Yield
Company (High Fusion)n/a
Market Bottom 25% (CA)2.0%
Market Top 25% (CA)6.1%
Industry Average (Pharmaceuticals)2.6%
Analyst forecast in 3 Years (High Fusion)n/a

Notable Dividend: Unable to evaluate FUZN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate FUZN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if FUZN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if FUZN's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as FUZN has not reported any payouts.

Discover strong dividend paying companies


How experienced are the management team and are they aligned to shareholders interests?


Average management tenure


John Durfy (56 yo)





Mr. John J. Durfy, CFA, CPA has been Chief Executive Officer of High Fusion Inc. (formerly known as Nutritional High International Inc.) since March 2, 2020 and has been its Director since May 28, 2020. Mr...

CEO Compensation Analysis

John Durfy's Compensation vs High Fusion Earnings
How has John Durfy's remuneration changed compared to High Fusion's earnings?
DateTotal Comp.SalaryCompany Earnings
Apr 30 2022n/an/a


Jan 31 2022n/an/a


Oct 31 2021n/an/a


Jul 31 2021CA$480kCA$240k


Apr 30 2021n/an/a


Jan 31 2021n/an/a


Oct 31 2020n/an/a


Jul 31 2020CA$100kCA$100k


Compensation vs Market: John's total compensation ($USD349.61K) is above average for companies of similar size in the Canadian market ($USD177.70K).

Compensation vs Earnings: John's compensation has been consistent with company performance over the past year.

Leadership Team

Experienced Management: FUZN's management team is considered experienced (3.3 years average tenure).

Board Members

Experienced Board: FUZN's board of directors are considered experienced (6 years average tenure).


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Recent Insider Transactions

CNSX:FUZN Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
13 Apr 22SellCA$1,050Brian PresementIndividual21,000CA$0.05
11 Apr 22SellCA$9,344Brian PresementIndividual179,000CA$0.055
17 Feb 22BuyCA$43,324Robert WilsonIndividual722,076CA$0.06
16 Feb 22BuyCA$252,898Adam SzwerasIndividual4,214,954CA$0.06
16 Feb 22BuyCA$463,867Adam SzwerasIndividual7,731,083CA$0.06
16 Feb 22BuyCA$101,159Brian PresementIndividual1,685,982CA$0.06
16 Feb 22BuyCA$533,327John DurfyIndividual8,888,743CA$0.06
31 Jan 22BuyCA$4,572John DurfyIndividual70,336CA$0.065

Ownership Breakdown

What is the ownership structure of FUZN?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders37,027,91718.7%
Private Companies60,513,61030.5%
General Public100,794,10950.8%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 273%.

Top Shareholders

Top 8 shareholders own 49.18% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
OutCo Labs Inc.
60,513,610CA$1.2m0%no data
Adam Szweras
13,031,453CA$260.6k0%no data
John Durfy
8,888,743CA$177.8k0%no data
Lincoln Fish
7,610,400CA$152.2k0%no data
Robert Wilson
5,871,388CA$117.4k0%no data
Brian Presement
1,523,333CA$30.5k-11.61%no data
Billy Morrison
100,875CA$2.0k0%no data
Aaron Johnson
1,725CA$34.50%no data

Company Information

High Fusion Inc.'s employee growth, exchange listings and data sources

Key Information

  • Name: High Fusion Inc.
  • Ticker: FUZN
  • Exchange: CNSX
  • Founded: 2004
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: CA$3.967m
  • Shares outstanding: 198.34m
  • Website:


  • High Fusion Inc.
  • 77 King Street West
  • Suite 2905
  • Toronto
  • Ontario
  • M5K 1H1
  • Canada


TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
FUZNCNSX (Canadian National Stock Exchange)YesSub-Ordinate Voting SharesCACADApr 2015
SPLI.FOTCPK (Pink Sheets LLC)YesSub-Ordinate Voting SharesUSUSDApr 2015
2NUDB (Deutsche Boerse AG)YesSub-Ordinate Voting SharesDEEURApr 2015

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/10/02 00:00
End of Day Share Price2022/09/30 00:00
Annual Earnings2021/07/31

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.